324 related articles for article (PubMed ID: 22289136)
1. IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia.
Bulian P; Rossi D; Forconi F; Del Poeta G; Bertoni F; Zucca E; Montillo M; Pozzato G; D'Arena G; Efremov DG; Marasca R; Lauria F; Gaidano G; Gattei V; Laurenti L
J Transl Med; 2012 Jan; 10():18. PubMed ID: 22289136
[TBL] [Abstract][Full Text] [Related]
2. Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia.
Li H; Yi SH; Xiong WJ; Liu HM; Lyu R; Wang TY; Liu W; Zhong SZ; Yu Z; Zou DH; Xu Y; An G; Li ZJ; Qiu LG
Chin Med J (Engl); 2017 Jan; 130(2):135-142. PubMed ID: 28091403
[TBL] [Abstract][Full Text] [Related]
3. The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia.
Gladstone DE; Blackford A; Cho E; Swinnen L; Kasamon Y; Gocke CD; Griffin CA; Bolaños-Meade J; Jones RJ
Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):132-7. PubMed ID: 22285608
[TBL] [Abstract][Full Text] [Related]
4. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
Delgado J; Doubek M; Baumann T; Kotaskova J; Molica S; Mozas P; Rivas-Delgado A; Morabito F; Pospisilova S; Montserrat E
Am J Hematol; 2017 Apr; 92(4):375-380. PubMed ID: 28120419
[TBL] [Abstract][Full Text] [Related]
5. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
[TBL] [Abstract][Full Text] [Related]
6. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.
Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J
Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198
[TBL] [Abstract][Full Text] [Related]
7. High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival.
Kotaskova J; Tichy B; Trbusek M; Francova HS; Kabathova J; Malcikova J; Doubek M; Brychtova Y; Mayer J; Pospisilova S
J Mol Diagn; 2010 May; 12(3):328-34. PubMed ID: 20228263
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
[TBL] [Abstract][Full Text] [Related]
9. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis.
Athanasiadou A; Stamatopoulos K; Tsompanakou A; Gaitatzi M; Kalogiannidis P; Anagnostopoulos A; Fassas A; Tsezou A
Cancer Genet Cytogenet; 2006 Jul; 168(2):109-19. PubMed ID: 16843100
[TBL] [Abstract][Full Text] [Related]
10. Serum carbohydrate antigen 125 is not an independent prognostic factor in patients with chronic lymphocytic leukemia.
Zou ZJ; Fan L; Wang L; Zhang R; Zhang LN; Yang S; Li JY; Xu W
Cancer Biomark; 2012; 12(4):169-76. PubMed ID: 23568007
[TBL] [Abstract][Full Text] [Related]
11. Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice.
Doubek M; Mayer J; Obrtlíková P; Smolej L; Cmunt E; Schwarz J; Brejcha M; Kozmon P; Pospíšilová S; Brychtová Y; Pospíšil Z; Trněný M
Eur J Haematol; 2011 Aug; 87(2):130-7. PubMed ID: 21535162
[TBL] [Abstract][Full Text] [Related]
12. Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia.
Gladstone DE; Swinnen L; Kasamon Y; Blackford A; Gocke CD; Griffin CA; Meade JB; Jones RJ
Leuk Lymphoma; 2011 Oct; 52(10):1873-81. PubMed ID: 21851216
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin gene rearrangements and mutational status in argentinian patients with chronic lymphocytic leukemia.
Stanganelli C; Travella A; Bezares R; Slavutsky I
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):447-457.e2. PubMed ID: 23665144
[TBL] [Abstract][Full Text] [Related]
14. Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study.
Gentile M; Cutrona G; Mosca L; Matis S; Fabris S; Lionetti M; Ilariucci F; Zupo S; Musolino C; Levato L; Molica S; Di Raimondo F; Vincelli I; Di Rienzo N; Pesce EA; Angrilli F; Federico M; Neri A; Ferrarini M; Morabito F
Am J Hematol; 2014 Jul; 89(7):743-50. PubMed ID: 24711230
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center.
Falchi L; Keating MJ; Wang X; Coombs CC; Lanasa MC; Strom S; Wierda WG; Ferrajoli A
Cancer; 2013 Sep; 119(17):3177-85. PubMed ID: 24022787
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
[TBL] [Abstract][Full Text] [Related]
17. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.
Wierda WG; O'Brien S; Wang X; Faderl S; Ferrajoli A; Do KA; Garcia-Manero G; Cortes J; Thomas D; Koller CA; Burger JA; Lerner S; Schlette E; Abruzzo L; Kantarjian HM; Keating MJ
J Clin Oncol; 2011 Nov; 29(31):4088-95. PubMed ID: 21969505
[TBL] [Abstract][Full Text] [Related]
18. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
[TBL] [Abstract][Full Text] [Related]
19. Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia.
Visentin A; Facco M; Frezzato F; Castelli M; Trimarco V; Martini V; Gattazzo C; Severin F; Chiodin G; Martines A; Bonaldi L; Gianesello I; Pagnin E; Boscaro E; Piazza F; Zambello R; Semenzato G; Trentin L
Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):612-20.e1-5. PubMed ID: 26233718
[TBL] [Abstract][Full Text] [Related]
20. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S
J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]